The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma

Gynecologic Oncology

Volumn 77, Issue 1, 2000, Pages 55-65

  Cirisano Jr , Frank D ^a   Robboy, Stanley J ^a   Dodge, Richard K ^a   Bentley, Rex C ^a   Krigman, Hannah R ^a   Synan, Ingrid S ^a   Soper, John T ^a   Clarke Pearson, Daniel L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clear cell carcinoma; Endometrial cancer; Papillary serous carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL;

EID: 0342699652     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5737     Document Type: Article

References (65)

1. Lauchlan S C. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med. 105:1981;615-618.
2. Hendrickson M, Ross J, Eifel P J, Cox R S, Martinez A, Kempson R. Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Gynecol Oncol. 13:1982;373-392.
3. Mathews R P, Hutchinson-Colas J, Maiman M, Fruchter R G, Gates J, Gibbon D, Remy J C, Sedlis A. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol. 65:1997;206-212.
4. Plaxe S C, Saltzstein S L. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol. 65:1997;8-12.
5. Christopherson WN Alberhasky R C, Connely P J. Carcinoma of the endometrium. I. A clinicopathological study of clear cell carcinoma and secretory carcinoma. Cancer. 49:1982;1511-1514.
6. Kurman R J, Scully R E. Clear cell carcinoma of the endometrium: analysis of 21 cases. Cancer. 37:1976;872-875.
7. Silverberg S G, DeGiorgi L S. Clear cell carcinoma of the endometrium: clinical-pathological and ultrastructural findings. Cancer. 31:1973;1127-1130.
8. Abeler V M, Kjorstad K E. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 40:1991;207-217.
9. Carcangiu M L, Chambers J T. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol. 14:1995;30-38.
10. Webb G A, Lagios M D. Clear cell carcinoma of the endometrium. Am J Obstet Gynecol. 156:1987;1486-1491.
11. Abeler V M, Vergote I B, Kjorstad K E, Trope C G. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 78:1996;1740-1747.
12. Morrow C P, Bundy B N, Kurman R J, Creasman W T, Heller P, Homesley H D, Graham J E. Relationship between surgical-pathologic risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 40:1991;55-65.
13. Sall S, Sonnenblick B, Stone M L. Factors affecting survival of patients with endometrial adenocarcinoma. Am J Obstet Gynecol. 107:1970;116-123.
14. Shah A, Green T H Jr. Evaluation and current management of endometrial carcinoma. Obstet Gynecol. 39:1972;500-509.
15. Figge D C, Otton P M, Tamimi H K, Greer B E. Treatment variables in the management of endometrial cancer. Am J Obstet Gynecol. 146:1983;495-500.
16. Creasman W T, Morrow C P, Bundy B N, Homesley H D, Graham J E, Heller P B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer. 60:1987;2035-2041.
17. Int J Gynaecol Obstet. 9:1971;172-174.
18. Poulsen, H, Taylor, C, W, Sobin, L, H, International histologic classification of tumors. No 13. Histologic typing of female genital tract tumors, World Health Organization, Geneva, 1975.
19. Zaino R J, Kurtman R, Herbald D. The significance of squamous differentiation. Cancer. 68:1991;2293-2296.
20. Abeler U A, Kjorstad K E. Endometrial adenocarcinoma with squamous cell differentiation. Cancer. 69:1992;488-492.
21. Sherman M E, Bitterman P, Rosenshein N B, Delgado G, Kurman R J. Uterine papillary serous carcinoma, a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 16:1992;600-610.
22. Carcangiu M L, Chambers J T. Uterine papillary serous carcinoma: A study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and comcomitant ovarian carcinoma. Gynecol Oncol. 47:1992;298-303.
23. Creasman W T. Revision in classification by International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol. 1992;167-857.
24. Armitage P. Statistical Methods in Medical Research. 1971;Blackwell Sci, London.
25. Simon R, Lee Y J. Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep. 66:1982;37-42.
26. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
27. Peto R, Pike M C, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 35:1977;1-39.
28. Tarone R E. Tests for trend in life table analysis. Biometrika. 62:1975;679-682.
29. Cox D R. Regression models and life tables. J R Stat Soc B. 34:1972;187-202.
30. Goff B A, Kato D, Schmidt R A, Ek M, Ferry J A, Muntz H G, Cain J M, Tamimi H K, Figge D C, Greer B E. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 54:1994;264-268.
31. Kato D T, Ferry J A, Goodman A, Sullinger J, Scully R E, Goff B A, Fuller A F, Rice L W. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 59:1995;384-389.
32. Gallion H H, van Nagell J R Jr, Powell D F, Donaldson E S, Higgins R V, Kryscio R J, Pavlik E J, Nelson K. Stage I serous papillary carcinoma of the endometrium. Cancer. 63:1989;2224-2228.
33. Gitsch G, Friedlander M L, Wain G V, Hacker N F. Uterine papillary serous carcinoma. Cancer. 75:1995;2239-2243.
34. Lawrence C, Tessaro I, Durgerian S. Smoking, body weight, and early-stage endometrial cancer. Cancer. 49:1987;1665-1669.
35. Lesko S M, Rosenberg L, Kaufman D W. Cigarette smoking and the risk of endometrial cancer. N Engl J Med. 313:1985;593-596.
36. Cirisano F D, Robboy S J, Dodge R K, Bentley R C, Krigman H R, Synan I S, Soper J T, Clarke-Pearson D L. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid. Gynecol Oncol. 74:1999;385-394.
37. Christman J E, Kapp D S, Hendrickson M R, Hoves H E, Ballon S C. Therapeutic approaches to uterine serous papillary carcinoma: a preliminary report. Gynecol Oncol. 26:1987;228-235.
38. Frank A H, Tseng P C, Haffty B G, Papadopoulos D P. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. Cancer. 68:1991;1516-1519.
39. Mallipeddi P, Knapp D S, Teng N N. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer. 71:1993;3076-3081.
40. Rosenberg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol. 48:1993;32-47.
41. Levenback C, Burke T W, Silva E, Morris M, Gershenson D M. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol. 46:1992;317-321.
42. Price V F, Chambers S K, Carcangiu M L, Kohorn E I, Schwartz P E, Chambers J T. Intravenous cisplatin, doxorubicin and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 51:1993;383-389.
43. Smith M R, Peters W A III, Drescher C W. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol. 170:1994;1677-1681.
44. Turner B C, Knisely J PS, Kacinski B M, Haffty B G. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192IR) and chemotherapy. Int J Radiat Oncol Biol Phys. 40:1998;77-84.
45. Nordstrom B, Strang P, Lindgren A, Bergstrom R, Tribukait B. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res. 16:1996;899-904.
46. Konski A A, Domenico D, Irving D, Tyrkus M, Neisler J, Phibbs G, Mah J, Eggleston W. Clinicopathologic correlation of DNA flow cytometric content analysis (DFCA), surgical staging, and estrogen/progesterone receptor status in endometrial adenocarcinoma. Am J Clin Oncol. 19:1996;164-168.
47. Miller B, Umpierre S, Tornos C, Burke T. Histologic characterization of uterine papillary serous adenocarcinoma. Gynecol Oncol. 56:1995;425-429.
48. Boyd J A, Siegal G P, Kaufman D G. Comparison of continuous human cell culture lines derived from papillary endometrial carcinoma and typical adenocarcinoma. Proc Am Assoc Cancer Res. 28:1987;29-31.
49. Khalifa M A, Mannel R S, Haraway S D, Walker J, Min K W. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 53:1994;84-92.
50. Caduff R F, Svoboda-Newman M S, Bartos R E, Ferguson A W, Frank T S. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol. 22:1998;319-326.
51. Sherman M E, Bur M E, Kurman R J. P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 26:1995;1268-1274.
52. Bancher-Todesca D, Gitsch G, Williams K E, Kohlberger P, Neunteufel W, Obermair A, Heinze G, Breitenecker G, Hacker N F. P53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma. Gynecol Oncol. 71:1998;59-63.
53. Berchuck A, Maxwell G L, Risinger J I, Carney M E, Hayes K, Dodge R K, Barrett C. Mutation of the PTEN and B-catenin genes is a feature of some endometrioid endometrial cancers. Eur J Gynecol Oncol XX. 59:1999.
54. Corn B W, Lanciano R M, D'Agostino R, Kiggundu E. The relationship of local and distant failure from endometrial cancer: defining a clinical paradigm. Gynecol Oncol. 66:1997;411-416.
55. Lutz M H. Endometrial carcinoma: a new method of classification of therapeutic and prognostic significance. Gynecol Oncol. 6:1978;83.
56. Tseng P, Sprance H, Carcangu M, Chambers J P, Schwartz P. Use of CA-125, NB/70K and LSA in monitoring uterine papillary serous carcinoma. Gynecol Oncol. 32:1989;122-125.
57. Chambers J T, Merino M, Kohorn E I, Peschel R E, Schwartz P E. Uterine papillary serous carcinoma. Obstet Gynecol. 69:1987;109-113.
58. Grice J, Ek M, Greer B, Koh W, Muntz H G. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 69:1998;69-73.
59. Hanson M B, Van Nagell J R Jr, Powell D E, Donaldson E S, Gallion H, Merhige M, Pavlik E J. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer. 1985;1753-1757.
60. Girardi F, Petru E, Heydarfadai M, Haas J, Winter R. Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol Oncol. 49:1993;177-181.
61. Kilgore L C, Partridge E E, Alvarez R D, Austin J M. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 56:1995;29-33.
62. Int J Gynecol Cancer. 6:1996;102-107.
63. Rose P G, Cha S D, Tak W K, Fitzgerald T. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys. 24:1992;223-237.
64. Chuang L, Burke T W, Tornos C. Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes. Gynecol Oncol. 58:1995;189-193.
65. Trimble E L, Kosary C, Park R C. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol. 71:1998;340-343.